Rationale: Atherosclerosis proceeds through a multistep reaction that begins with endothelial injury caused by a host of stress signals, among which oxidized low-density lipoprotein (oxLDL) plays a critical role. OxLDL disrupts normal functionality of the endothelium by upregulating adhesion molecules (eg, ICAM-1) and concomitantly downregulating endothelial nitric oxide synthase (eNOS) expression. The transcriptional modulator that mediates the cellular response to oxLDL remains largely obscure.
A therosclerosis is a polygenic pathology progressing through a series of interdependent processes that eventually result in the formation in the aortic artery of an atheromatous plaque. 1 A host of extrinsic and intrinsic insults, which include oxidative stress, inflammatory stress, shear stress, and ischemic hypoxic stress, coordinately act on the vasculature to promote the atherogenic agenda. 2 Upregulation of oxidized low-density lipoprotein (oxLDL) levels is a hallmark feature of atherosclerosis. 3 Accumulation of ox-LDL, acting as a stress signal, alters the transcriptome and hence the function of the vasculature, contributing to the development and progression of atherosclerotic injury. 4 It is generally accepted that chronic inflammation plays a major role in atherosclerosis whereas injury to the endothelial layer of vessels is considered a pivotal step in initiating the inflammatory response. 5 For proinflammatory leukocytes to gain access to the vasculature, the expression of adhesion molecules (ICAM, VCAM) is markedly induced by oxLDL to facilitate the infiltration of leukocytes, which in turn perpetuates the chronic inflammation and aggravates atherosclerotic injury. 6 Meanwhile, expression of endothelial nitric oxide synthase (eNOS), which, through producing NO, affords the endothelium much of its physiological function, is severely disrupted by various pathogenic insults including elevated oxLDL levels paralleling the loss of vascular tone during atherogenesis. 7 Thus, oxLDL can impair endothelial function by stimulating ICAM and VCAM transcription while suppressing eNOS transcription. The specific transcriptional modulator(s) that drives the differential expression profiles in the endothelium during atherogenesis as well as the underlying mechanism, however, is not fully appreciated.
Myocardin-related transcription factor (MRTF)-A, also known as MKL1 (megakaryoblastic leukemia 1), belongs to a group of transcriptional regulators that also include myocardin and MRTF-B and is involved in the organogenesis of the cardiovascular system with a prominent role in steering the development and function of smooth muscle cells (SMCs). 8 of stress induced pathophysiological processes in the vasculature. For instance, platelet-derived growth factor (PDGF), a potent proatherogenic stress stimulus, drives the phenotypic switch of SMC by dissociating MRTF-A from the promoters of SMC signature genes. 9 MRTF-A also mediates the adaptive response in bladder SMC challenged with shear stress. 10 However, the role of MRTF-A in endothelial cells has yet to be elucidated. Here we report that MRTF-A is activated and mediates the endothelial injury by oxLDL. Our data provide the first characterization of MRTF-A in the endothelium and expands the realm of MRTF-A functions in vascular pathophysiology.
Methods
An expanded Methods section is available in the Online Data Supplement at http://circres.ahajournals.org.
Briefly, human umbilical vein endothelial cells and primary aortic endothelial cells were maintained according to the vendors' recommendations. Promoter activity was measured by transfection reporter assays. Expression of mRNA and protein was measured by real-time quantitative PCR and Western blotting, respectively. Interaction between endothelial cells and leukocytes was assessed by leukocyte adhesion assay. eNOS activity was measured by the NO assay. Knockdown of endogenous proteins was mediated by either small interfering (si)RNA or short hairpin (sh)RNA. DNA binding was assayed by gel shift and chromatin immunoprecipitation (ChIP) assays.
Results

MRTF-A Is Activated by OxLDL in Endothelial Cells
To determine whether MRTF-A mediates the detrimental effects of oxLDL, we first probed the expression of MRTF-A in response to oxLDL in endothelial cells. As shown in Figure  1A , oxLDL significantly stimulated the expression of MRTF-A in a human umbilical vein endothelial cell line (HUVEC/EAhy926) as well as in human primary aortic endothelial cells (HAECs). Concomitantly, ICAM-1 expression was induced and eNOS expression was repressed by oxLDL. Increases in MRTF-A protein levels were primarily attributable to accelerated mRNA synthesis ( Figure 1B ; Online Figure I, A), owing to, at least in part, augmented transcription rate as oxLDL upregulated MRTF-A promoter activity in reporter assays ( Figure 1C ). In addition, oxLDL promoted the nuclear accumulation of MRTF-A ( Figure 1D ; Online Figure I , B and C).
To determine whether the effect of oxLDL was specific for MRTF-A, we also probed mRNA levels of several protein factors that are closely related to MRTF-A, namely myocardin, MRTF-B, and SRF, in endothelial cells challenged with oxLDL. As shown in Online Figure I (D), whereas SRF expression was significantly upregulated by oxLDL similar to MRTF-A, there was little change in MRTF-B expression. On other hand, myocardin, believed to be exclusively expressed in cells of smooth and cardiac muscle lineages, was not detectable either in the absence or presence of oxLDL. Together, these data suggest that oxLDL activates MRTF-A in endothelial cells, which may in turn facilitate its proatherogenic agenda.
MRTF-A Potentiates the Activation of Adhesion Molecules by OxLDL
Because adhesion molecules are upregulated by oxLDL and contribute to the initiation of endothelial injury during atherogenesis, we set to examine the role of MRTF-A in the transcriptional activation of these genes. MRTF-A, but not MRTF-B, activated the promoter activities of ICAM-1, ICAM-2, and VCAM-1 genes in a dose response manner ( 
OxLDL Promotes the Recruitment of MRTF-A to the ICAM-1 Promoter
To demarcate the region on ICAM-1 promoter where MRTF-A exerts its effect, ICAM-1 promoter constructs harboring serial deletions were used. MRTF-A activated ICAM-1 transcription only when a small region (Ϫ393/Ϫ176) is preserved ( Figure  3A ). Indeed, ChIP assays using primers spanning this region showed the binding of MRTF-A, which was further augmented by oxLDL; no amplification was detected using primers surrounding the first intron of the ICAM-1 gene, confirming the specificity of MRTF-A binding ( Figure 3B ).
Because RhoA, the small G protein that has been shown to induce the nuclear accumulation of MRTF-A, can be acti- Figure 3D ). Thus, it is likely that an oxLDL-RhoA-MRTF-A axis regulates the induction of adhesion molecules during endothelial injury.
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Figure 1. MRTF-A is activated by oxLDL in endothelial cells. A and B, HUVECs (EAhy926) (left) or aortic endothelial cells (right)
were treated with oxLDL (20 to 100 g/mL) and probed for protein (A) and mRNA (B) levels of MRTF-A, ICAM-1, and eNOS. MRTF-A protein expression from 3 independent experiments was corrected by ␤-actin levels for normalization and expressed as relative MRTF-A protein levels. Unfilled indicates control; light gray, oxLDL (20 g/mL); dark gray, oxLDL (50 g/mL); filled, oxLDL (100 g/mL). C, Luciferase construct driven by the human MRTF-A promoter (Ϫ1585/ϩ114) was transfected into HUVECs followed by treatment with oxLDL (20 to 100 g/mL). Luciferase activities were normalized by both protein concentration and GFP fluorescence. Data are presented as normalized relative luciferase unit (NRLU). *PϽ0.05. D, HAECs were treated with oxLDL (50 g/mL) for 24 hours. Cellular MRTF-A was visualized by immunofluorescence staining. The nuclei were counterstained with DAPI. The number of cells located in the nucleus in each group was counted using Image-Pro, and data were expressed as percentages compared with the overall cell count. Scale bar, 50 m.
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MRTF-A Is Recruited to the ICAM-1 Promoter by Nuclear Factor B
As a transcriptional cofactor without the ability to bind directly to DNA, MRTF-A relies on sequence-specific transcriptional factor(s) to be recruited to its targets. Therefore, we examined how MRTF-A is recruited to the ICAM-1 promoter. Bioinformatic analysis of the ICAM-1 promoter region (Ϫ393/Ϫ176) revealed a conserved binding element for the sequence-specific transcription factor nuclear factor (NF)-B (Online Figure Figure 4D through 4F), pointing to a functional interplay between MRTF-A and p65. In further support of this notion, MRTF-A augmented the luciferase activity driven by 2 tandem repeats of the NF-B response element (Online Figure IV, F) . In aggregate, these data suggest that p65 recruits MRTF-A to the ICAM-1 promoter in response to increased oxLDL levels.
SRF Is Essential for ICAM-1 Transactivation by OxLDL
It is well documented that MRTF-A interacts with SRF to promote gene transcription specific for the smooth muscle cell lineage 12 and that SRF physically and functionally interacts with p65. 13 Because it was observed that SRF expression was induced by oxLDL in endothelial cells, we examined the role of SRF in MRTF-A mediated ICAM-1 transactivation. Disruption of en- There is no conserved SRF binding element (CArG) on the proximal ICAM-1 promoter (Ϫ393/Ϫ176), indicating that SRF likely impacts ICAM-1 transcription through other mechanisms than direct DNA binding. Sequential immunoprecipitation assay and gel shift assay showed that MRTF-A, p65, and SRF formed a tertiary complex ( Figure 5D ; Online Figure V, D) . In addition, oxLDL promoted the binding of SRF to the same region that MRTF-A and p65 occupy on the ICAM-1 promoter ( Figure 5E ). Similar to what was observed for MRTF-A, oxLDL also augmented the interaction between SRF and p65 on the ICAM-1 promoter as demonstrated by Re-ChIP (Online Figure V, E) , whereas knockdown of p65 markedly disrupted the recruitment of SRF to the ICAM-1 promoter (Online Figure V, F) . Combined, these data clearly illustrated that oxLDL induced the formation of a p65/MRTF-A/SRF complex on the ICAM-1 promoter to induce its transcription.
MRTF-A Binds to eNOS Promoter and Suppresses Its Transcription in Response to OxLDL
eNOS dependent NO production plays a significant role in endothelial physiology and is impaired by oxLDL during atherogenesis. We then sought to determine the effect of MRTF-A on the expression and activity of eNOS. Under basal conditions, MRTF-A modestly suppressed the activity of eNOS promoter whereas its activity was markedly enhanced by oxLDL ( Figure  6A ). oxLDL also repressed endogenous eNOS mRNA better when cells were infected with retrovirus carrying MRTF-A ( Figure 6B ). In contrast, both MRTF-A siRNA and DN-MRTF-A alleviated the repression of eNOS by oxLDL ( Figure  6C ; Online Figure VI , A through C). Moreover, depletion of MRTF-A in endothelial cells restored NO bioavailability in the presence of oxLDL ( Figure 6D ; Online Figure VI, D) . Harnessing a similar strategy, we identified a short stretch of DNA (Ϫ430/Ϫ168) on the eNOS promoter as the response element for MRTF-A (Online Figure VII, A) and ChIP assays in both HUVECs and HAECs confirmed that oxLDL preferentially stimulated the binding of MRTF-A to this region but not to the first intron of the eNOS gene ( Figure 6E ). Likewise, MRTF-A requires functional RhoA signaling to be recruited to the eNOS promoter as forced expression of RhoA DN prevented the binding of MRTF-A (Online Figure VII, B) . Conversely, RhoA seemed to be dependent on MRTF-A to suppress eNOS expression (Online Figure VII, C and D) . Taken together, our data suggest that MRTF-A contributes to oxLDL-dependent impairment of vascular tone by repressing eNOS transcription in endothelial cells in a RhoA-dependent manner.
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MRTF-A-Mediated Transcription Involves Differential Epigenetic Alterations
At the chromatin level, altered epigenetic modifications are responsible for differential gene expression. We next probed how MRTF-A might affect the epigenetic alterations taking place on the ICAM-1 and eNOS promoters. In keeping with the expression pattern of ICAM-1, active histone modifications (acetylated histones H3 and H4, dimethylated histone H3 lysine 4) were preferentially induced by oxLDL on its promoter whereas levels of trimethylated H3 lysine 9, usually associated with transcriptional repression, were suppressed ( Figure 7A ; Online Figure VIII, A) . Intriguingly, this set of epigenetic alterations was completely reversed when MRTF-A levels were knocked down by siRNA. Knockdown of endogenous SRF with siRNA had a similar impact (Online Figure 5 . SRF is essential for ICAM-1 transactivation by oxLDL. A, An ICAM-1 promoter construct was transfected into HUVECs and HEK293 cells with MRTF-A, SRF siRNA (siSRF), or scrambled siRNA (SCR). Luciferase activities expressed as NRLU. B, An ICAM-1 promoter construct was transfected into HUVECs with siSRF or SCR followed by treatment with oxLDL. Luciferase activities expressed as NRLU. C, SiSRF or SCR was transfected into HUVECs followed by treatment with oxLDL. ICAM-1 expression levels were measured by qPCR and Western. *PϽ0.05. D, Electrophoresis mobility shift assay (EMSA) was performed with a DNA probe harboring the p65 site as described in Methods. E, HAECs were treated with or without oxLDL for 24 hours. ChIP assays were performed with anti-SRF. Precipitated DNA was amplified by qPCR with primers spanning the ICAM-1 promoter region or the first intron. *PϽ0.05. Figure VIII , B and C). In sharp contrast, basal levels of active histone marks were higher on the eNOS promoter in the absence of oxLDL ( Figure 6B ). Treatment with oxLDL erased the active marks and put in place repressive histone modifications only in the presence of endogenous MRTF-A ( Figure 7B ; Online Figure VIII, D) . SRF depletion, however, did not alter the histone modifications on the eNOS promoter (data not shown). Thus, our data indicate that the MRTF-A is central to oxLDL-orchestrated epigenetic regulation of gene expression in endothelial cells.
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Discussion
OxLDL is present in the circulation as well as in the atherosclerotic plaque. 3, 14 It is believed to be a critical risk Figure 6 . MRTF-A binds to eNOS promoter and suppresses its transcription in response to oxLDL. A, An eNOS promoter construct (Ϫ2091) was transfected into HUVECs with or without MRTF-A followed by oxLDL (20 g/mL) treatment. Luciferase activities expressed as NRLU. B, HAECs were infected with retrovirus carrying MRTF-A followed by oxLDL (20 g/mL) treatment. eNOS mRNA and protein levels were determined by real-time qPCR and Western. *PϽ0.05. C, HUVECs and HAECs were transfected with MRTF-A siRNA or scrambled siRNA followed by oxLDL (50 g/mL) treatment. eNOS mRNA and protein levels were determined by real-time qPCR and Western. *PϽ0.05. D, HAECs were transfected with MRTF-A siRNA or scrambled siRNA followed by oxLDL (50 g/mL) treatment. eNOS activity was measured by NO assay as described in Methods. *PϽ0.05. E, HAECs were treated with oxLDL (20 to 100 g/mL) for 24 hours. ChIP assays were performed with anti-MRTF-A. Precipitated DNA was amplified by qPCR with primers spanning the eNOS promoter or the first intron. *PϽ0.05.
Figure 7. MRTF-A-mediated transcriptional events involve differential epigenetic alterations. A and B,
HAECs were transfected with MRTF-A siRNA (#1) or scrambled siRNA followed by treatment with oxLDL (50 g/mL). ChIP assays were performed with indicated antibodies. Precipitated DNA was amplified with qPCR primer/probe sets for ICAM-1 (A) and eNOS (B) promoters as described in Methods.
factor/biomarker that links several concurrent pathophysiological processes including chronic inflammation, metabolic disorder, and oxidative stress during atherogenesis rendering the vasculature dysfunctional. 15 Among many of its deleterious effects, oxLDL-induced endothelial injury is often considered a predisposing trigger leading up to further progression and deterioration of atherosclerosis. 16 Here we present evidence that MRTF-A, a transcriptional modulator, is responsible for oxLDL induced endothelial injury by mediating key transcriptional events in the endothelium. We demonstrate here that regulation of MRTF-A by oxLDL is at least 4-fold. First, oxLDL increased MRTF-A expression at the transcriptional level ( Figure 1A through 1C ). Second, oxLDL prompted nuclear accumulation of MRTF-A ( Figure 1D ; Online Figure I , B and C). Third, oxLDL increased the occupancy of MRTF-A on target promoters ( Figure 3B and Figure 6E ). Finally, oxLDL promoted the interaction between MRTF-A and p65 on the ICAM-1 promoter ( Figure 4C ). Accumulating evidence has linked MRTF-A to cellular adaptation to stress cues. In the cardiovascular system, upregulation of MRTF-A levels has been linked to increased incidence of coronary artery disease. 17 More recently, 2 independent groups have demonstrated that MRTF-A deficiency attenuates tissue impairment and protects against myocardial infarction and cardiac hypertrophy. 18, 19 Our data presented here allude to the notion that activation of MRTF-A underscores the maladaptation of endothelial cells in response to stress exerted by oxLDL, indicating endothelial-specific loss-of-function of MRTF-A would alleviate atherosclerotic injury. Future studies using tissue-specific knockout model of MRTF-A and high-output expression profiling may shed more light on the vascular pathophysiology of MRTF-A.
MRTF-A forges extensive protein-protein interactions inside the cell, which in turn affect its subcellular localization, and/or target specificity. To date, most studies have focused on the interaction between MRTF-A and SRF, which recruits MRTF-A to the conserved CArG sequence found in many SMC-specific genes. There is no conserved CArG element in the proximal ICAM-1 promoter (Ϫ393/Ϫ176). Instead, we demonstrate here that MRTF-A is recruited to the ICAM-1 promoter by interacting with NF-B/p65. It was previously reported that myocardin, a closely related family member, interacts with p65 and suppresses smooth muscle cell proliferation. 20 Because MRTF-A, unlike myocardin, is universally expressed, this interaction is likely to have broader physiological and/or pathological implications. Intriguingly, by chromatin immunoprecipitation coupled with microarray (ChIP-chip), several p65 binding sites have been located on the proximal promoter and within the first intron of the MKL1/MRTF-A gene. 21 In light of our new data, we intend to propose a scenario wherein MRTF-A, as a downstream target of p65, reciprocally fine-tunes p65 activity. A wellestablished example in support of this hypothesis is the nuclear receptor peroxisome proliferator activated receptor (PPAR)␥. PPAR␥ upregulates the expression of CAAT/ enhancer binding protein (C/EBP)␣ and cooperate with the latter to dictate adipogenesis in preadipocyte whereas it activates and facilitates CIITA to regulate matrix production and chronic inflammation in smooth muscle cells. [22] [23] [24] Interestingly, SRF forms a tertiary complex with MRTF-A and p65 and is brought to the ICAM-1 promoter by p65 ( Figure 5 ; Online Figure V) . Previously, it has been shown that p65 interacts with SRF and enhances SRF-driven transcription without binding to DNA directly. 13 Our data suggest that the functional interaction between SRF and p65 could be reciprocal such that they act as coactivators for each other. It remains to be determined at a genome-wide scale how the p65/MRTF-A duet (and possibly SRF) regulates human oxLDL binds to its transmembrane receptor (LOX and/or CD36) and activates RhoA, which in turn prompts the nuclear accumulation of MRTF-A. MRTF-A is recruited to target promoters and dictates transcriptional outcome by interacting with sequencespecific transcription factors (eg, p65/RelA) and epigenetic factors (eg, Brg1) to induce differential alterations in histone modifications on target promoters. oxLDL can also upregulate MRTF-A expression likely through promoting the binding of p65 to the MRTF-A gene promoter. As a result, expression of adhesion molecules is upregulated whereas expression of eNOS is downregulated. Enhancement of leukocyte adhesion and reduction of NO production ensue, eventually leading to a decompensatory phenotype of the vascular endothelium.
pathophysiology. On the other hand, we demonstrate that MRTF-A directly binds to the eNOS promoter and represses its transcription in response to oxLDL likely involving epigenetic maneuverings. It remains enigmatic what sequence-specific transcription factor (more precisely, repressor) recruits MRTF-A to the eNOS promoter. Although several transcriptional repressors for the eNOS gene, including STAT3, 25 AP-1, 26 and ATF2, 27 have been identified, their binding sites do not overlap with the putative MRTF-Aresponse element (Ϫ430/Ϫ168). Of note, there is no conserved SRF element in the proximal eNOS promoter and depletion of SRF had no impact on eNOS expression and epigenetic alterations on the eNOS promoter (data not shown). Ongoing investigation in our laboratory harnessing DNA affinity chromatography coupled with mass spectrometry will hopefully resolve this issue.
Epigenetic alterations are associated with differential gene expression patterns in the vasculature. 28, 29 Little is known, however, about the molecular switch that dictates the epigenetic alterations leading up to atherogenesis. Our data suggest that MRTF-A is a master coordinator in the epigenetic regulation of ICAM-1 and eNOS expression in response to oxLDL (Figure 7) . MRTF-A is known to interact with members of the epigenetic machinery, including the ATPdependent chromatin remodeling proteins (Brg1 and Brm) and the histone demethylase Jmjd1a. 30, 31 Our preliminary data suggest that Brg1 and, to a lesser extent, Brm are required for MRTF-A dependent epigenetic alterations and transcriptional outcomes in endothelial cells (Fang F. and Xu Y., unpublished data). Several outstanding questions regarding the precise maneuvering that underlies the epigenetic regulation of gene expression by MRTF-A in response to stress await answers. For instance, it remains enigmatic how MRTF-A provokes 2 opposite sets of epigenetic alterations that herald transcriptional activation and repression simultaneously. Our data favor a model (Figure 8) where MRTF-A is recruited to multiple spatially separated transcriptional foci (zones) that differ in cofactor and modification enzyme. Recent reports indicate that MRTF-A is both SUMOylated and phosphorylated in vivo. 32, 33 Because protein posttranslational modifications (PTM) including SUMOylation and phosphorylation are actively involved in the organization of nuclear compartments, 34 it is likely that the PTM machinery modifies and hence assigns MRTF-A to different loci to mediate either transcriptional activation or repression depending on the local enrichment of cofactors. Of note, several proteins that are important regulators of cardiovascular pathophysiology are subject to signal-induced modifications, which in turn affect their activities. PPAR␥, for instance, can promote lipid uptake of macrophages by activating the scavenger receptor gene CD36 while, at the same time, reining in the inflammatory response by downregulating iNOS transcription; only the latter requires ligand-dependent SUMOylation on lysine 365 of PPAR␥. 35 We have previously reported that CIITA, in response to the proinflammatory cytokine interferon-␥, modulates an array of key transcriptional events involved in atherogenesis including activation of MHC II genes and repression of collagen type I genes. 36 -38 Spatiotemporal control of CIITA activity is attributed to differential modifications including phosphorylation, ubiquitination, and acetylation. 39 Proteomic studies combined with animal models deficient in the PTM machinery may help unveil the precise mechanism whereby MRTF-A differentially regulates transcription in the vasculature.
In summary, we have delineated an oxLDL-MRTF-A axis that contributes to endothelial injury during atherogenesis. Because MRTF-A plays a major role in this process, therapeutic strategies targeting MRTF-A could serve as a potential treatment option to correct endothelial dysfunction.
